SEC Comment Letter for Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282) (SYRE) — May 22, 2017
Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282)
Date: May 22, 2017 · CIK: 0001636282 · Accession: 0000000000-17-017758
AI Filing Summary & Sentiment
Reasoning
Letter
May 17, 2017 David Lowe President and Chief Executive OfficerAeglea BioTherapeutics, Inc.901 S. MoPac ExpresswayBarton Oaks Plaza One, Suite 250Austin, TX 78746 Aeglea BioTherapeutics, Inc. Registration Statement on Form S-3Response Dated May 12, 2017File No. 333-217573Re: Dear Mr. Lowe: We have reviewed your May 12, 2017 response to our comment letter and have the following comment. In some of our comments, we may ask you to provide us with informationso we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts andcircumstances or do not believe an amendment is appropriate, please tell us why in yourresponse. After reviewing any amendment to your registration statement and the information you provide in response to the comment we may have additional comments. Registration Statement on Form S-3 Cover Page We acknowledge your response to prior comment 1, and your statement that there were 10,140,561 shares that were held by non-affiliates of the company on March 20, 2017. However, we note that you stated in your Form 10-K that as of June 30, 2016, the market value of your shares held by non-affiliates was approximately $24.6 million, based on the per share price of $4.86, which indicates that there were approximately 5 million sharesthat were held by non-affiliates at that time. We have not noted substantial changes inyour number of shares outstanding or a decrease in the holdings of your other significantshareholders since June 2016. Accordingly, please explain how you1.
David Lowe Aeglea BioTherapeutics, Inc. 2 PageMay 17, 2017 have changed your calculation of the market value of your non-affiliate shares and why. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence ofaction by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registrationstatement. Please contact Dorrie Yale at 202-551-8776 or Erin Jaskot, Special Counsel, at 202-551- 3442 with any questions. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
May 17, 2017
David Lowe
President and Chief Executive OfficerAeglea BioTherapeutics, Inc.901 S. MoPac ExpresswayBarton Oaks Plaza One, Suite 250Austin, TX 78746
Aeglea BioTherapeutics, Inc.
Registration Statement on Form S-3Response Dated May 12, 2017File No. 333-217573Re:
Dear Mr. Lowe:
We have reviewed your May 12, 2017 response to our comment letter and have the
following comment. In some of our comments, we may ask you to provide us with informationso we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts andcircumstances or do not believe an amendment is appropriate, please tell us why in yourresponse.
After reviewing any amendment to your registration statement and the information you
provide in response to the comment we may have additional comments.
Registration Statement on Form S-3
Cover Page
We acknowledge your response to prior comment 1, and your statement that there were
10,140,561 shares that were held by non-affiliates of the company on March 20, 2017. However, we note that you stated in your Form 10-K that as of June 30, 2016, the market
value of your shares held by non-affiliates was approximately $24.6 million, based on the
per share price of $4.86, which indicates that there were approximately 5 million sharesthat were held by non-affiliates at that time. We have not noted substantial changes inyour number of shares outstanding or a decrease in the holdings of your other significantshareholders since June 2016. Accordingly, please explain how you1.
David Lowe
Aeglea BioTherapeutics, Inc.
2 PageMay 17, 2017
have changed your calculation of the market value of your non-affiliate shares and why.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence ofaction by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registrationstatement.
Please contact Dorrie Yale at 202-551-8776 or Erin Jaskot, Special Counsel, at 202-551-
3442 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance